Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 7Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 79Carcinoma, Non-Small-Cell Lung 71Prostatic Neoplasms 68Neoplasms 52Multiple Myeloma 46Lung Neoplasms 42Colorectal Neoplasms 37Melanoma 32Lymphoma, Non-Hodgkin 30Pancreatic Neoplasms 29Neoplasm Metastasis 29Lymphoma 28Leukemia, Myeloid, Acute 27Squamous Cell Carcinoma of Head and Neck 26Ovarian Neoplasms 26Carcinoma, Renal Cell 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Endometrial Neoplasms 22Stomach Neoplasms 20Sarcoma 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Glioma 19Uterine Cervical Neoplasms 18Recurrence 18Rectal Neoplasms 18Lymphoma, Mantle-Cell 17Hematologic Neoplasms 17Head and Neck Neoplasms 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Autoimmune Diseases × 30 days × Clear all
NCT06359041 2026-05-18

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Cabaletta Bio

Phase 1/2 Active not recruiting
12 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡